Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian Mirkin

Showing results (81-90 of 104) with videos related to

Pageof 11
Sort By:
Obstetrics and Gynecology|May 3, 2013
Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trialJoAnn V Pinkerton, Jennifer A Harvey, Kaijie Pan, et al.
BMC Women'S Health|August 15, 2015
Prevalence of menopausal symptoms among mid-life women: findings from electronic medical recordsMatthew Sussman, Jeffrey Trocio, Craig Best, et al.
The Journal of Sexual Medicine|December 5, 2016
Response and Rebuttal to Editorial Comment on TX-004HR Improves Sexual Function as Measured by the Female Sexual Function Index in Postmenopausal Women with Vulvar and Vaginal Atrophy: The REJOICE TrialSheryl A Kingsberg, Leonard Derogatis, James A Simon, et al.
The Journal of Sexual Medicine|October 4, 2016
TX-004HR Improves Sexual Function as Measured by the Female Sexual Function Index in Postmenopausal Women With Vulvar and Vaginal Atrophy: The REJOICE TrialSheryl A Kingsberg, Leonard Derogatis, James A Simon, et al.
Menopause (New York, N.Y.)|December 22, 2016
TX-004HR vaginal estradiol has negligible to very low systemic absorption of estradiolDavid F Archer, Ginger D Constantine, James A Simon, et al.
Journal of Women'S Health (2002)|September 28, 2016
Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Vasomotor Symptoms in the Selective Estrogens, Menopause, and Response to Therapy TrialsDavid F Archer, Ellen W Freeman, Barry S Komm, et al.
Journal of Women'S Health (2002)|November 12, 2013
Evaluation of the efficacy and safety of bazedoxifene/conjugated estrogens for secondary outcomes including vasomotor symptoms in postmenopausal women by years since menopause in the Selective estrogens, Menopause and Response to Therapy (SMART) trialsJoann V Pinkerton, Lucy Abraham, Andrew G Bushmakin, et al.
Contraception|March 31, 2021
Segesterone acetate serum levels with a regression model of continuous use of the segesterone acetate/ethinyl estradiol contraceptive vaginal systemJames H Liu, Marlena Plagianos, David F Archer, et al.
Current Medical Research and Opinion|April 30, 2014
Indirect comparison of bazedoxifene vs oral bisphosphonates for the prevention of vertebral fractures in postmenopausal osteoporotic womenAlexandra G Ellis, Jean-Yves Reginster, Xuemei Luo, et al.
Menopause (New York, N.Y.)|May 31, 2021
Evaluation of endometrial progesterone receptor expression after 12 weeks of exposure to a low-dose vaginal estradiol insertSebastian Mirkin, James A Simon, James H Liu, et al.
Pageof 11

Showing results (81-90 of 104) with videos related to

Sort By:
Pageof 11
Obstetrics and Gynecology|May 3, 2013
Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trialJoAnn V Pinkerton, Jennifer A Harvey, Kaijie Pan, et al.
BMC Women'S Health|August 15, 2015
Prevalence of menopausal symptoms among mid-life women: findings from electronic medical recordsMatthew Sussman, Jeffrey Trocio, Craig Best, et al.
The Journal of Sexual Medicine|December 5, 2016
Response and Rebuttal to Editorial Comment on TX-004HR Improves Sexual Function as Measured by the Female Sexual Function Index in Postmenopausal Women with Vulvar and Vaginal Atrophy: The REJOICE TrialSheryl A Kingsberg, Leonard Derogatis, James A Simon, et al.
The Journal of Sexual Medicine|October 4, 2016
TX-004HR Improves Sexual Function as Measured by the Female Sexual Function Index in Postmenopausal Women With Vulvar and Vaginal Atrophy: The REJOICE TrialSheryl A Kingsberg, Leonard Derogatis, James A Simon, et al.
Menopause (New York, N.Y.)|December 22, 2016
TX-004HR vaginal estradiol has negligible to very low systemic absorption of estradiolDavid F Archer, Ginger D Constantine, James A Simon, et al.
Journal of Women'S Health (2002)|September 28, 2016
Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Vasomotor Symptoms in the Selective Estrogens, Menopause, and Response to Therapy TrialsDavid F Archer, Ellen W Freeman, Barry S Komm, et al.
Journal of Women'S Health (2002)|November 12, 2013
Evaluation of the efficacy and safety of bazedoxifene/conjugated estrogens for secondary outcomes including vasomotor symptoms in postmenopausal women by years since menopause in the Selective estrogens, Menopause and Response to Therapy (SMART) trialsJoann V Pinkerton, Lucy Abraham, Andrew G Bushmakin, et al.
Contraception|March 31, 2021
Segesterone acetate serum levels with a regression model of continuous use of the segesterone acetate/ethinyl estradiol contraceptive vaginal systemJames H Liu, Marlena Plagianos, David F Archer, et al.
Current Medical Research and Opinion|April 30, 2014
Indirect comparison of bazedoxifene vs oral bisphosphonates for the prevention of vertebral fractures in postmenopausal osteoporotic womenAlexandra G Ellis, Jean-Yves Reginster, Xuemei Luo, et al.
Menopause (New York, N.Y.)|May 31, 2021
Evaluation of endometrial progesterone receptor expression after 12 weeks of exposure to a low-dose vaginal estradiol insertSebastian Mirkin, James A Simon, James H Liu, et al.
Pageof 11